📣 VC round data is live. Check it out!
- Public Comps
- Yifan Pharmaceutical
Yifan Pharmaceutical Valuation Multiples
Discover Yifan Pharmaceutical's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Intellia Therapeutics, Iovance Biotherapeutics, Bausch Health, Jinyu Bio-Technology Co. and more.
Yifan Pharmaceutical Overview
About Yifan Pharmaceutical
Yifan Pharmaceutical Co Ltd is a China-based company engaged in R&D and production company focusing on the pharmaceutical and health sectors. Its vision is to develop drugs with definite clinical values, to help disease-afflicted patients regain health. The group focuses on four business areas such as biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs). The products of the company are Ryzneuta, Plerixafor Injection, Vincristine Sulfate, Skin Allergy Reli, and Others.
Founded
1994
HQ

Employees
1.5K
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialYifan Pharmaceutical Financials
Yifan Pharmaceutical reported last 12-month revenue of $785M and EBITDA of $139M.
In the same LTM period, Yifan Pharmaceutical generated $371M in gross profit, $139M in EBITDA, and $64M in net income.
Revenue (LTM)
Yifan Pharmaceutical P&L
In the most recent fiscal year, Yifan Pharmaceutical reported revenue of $759M and EBITDA of $129M.
Yifan Pharmaceutical is profitable as of last fiscal year, with gross margin of 47%, EBITDA margin of 17%, and net margin of 8%.
Financial data powered by Morningstar, Inc.
Yifan Pharmaceutical Stock Performance
Yifan Pharmaceutical has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Yifan Pharmaceutical's stock price is $1.53.
Yifan Pharmaceutical share price decreased by 1.2% in the last 30 days, and by 19.1% in the last year.
Yifan Pharmaceutical has an EPS (earnings per share) of $0.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -1.6% | -1.2% | -17.9% | -19.1% | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialYifan Pharmaceutical Valuation Multiples
Yifan Pharmaceutical trades at 2.7x EV/Revenue multiple, and 15.1x EV/EBITDA.
EV / Revenue (LTM)
Yifan Pharmaceutical Financial Valuation Multiples
As of June 3, 2026, Yifan Pharmaceutical has market cap of $2B and EV of $2B.
Yifan Pharmaceutical has a P/E ratio of 29.0x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Yifan Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Yifan Pharmaceutical Margins & Growth Rates
Yifan Pharmaceutical grew revenue by 10% and EBITDA by 18% in the last fiscal year.
In the most recent fiscal year, Yifan Pharmaceutical reported gross margin of 47%, EBITDA margin of 17%, and net margin of 8%.
Yifan Pharmaceutical Margins
Yifan Pharmaceutical Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Yifan Pharmaceutical Operational KPIs
Yifan Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Yifan Pharmaceutical's Rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Yifan Pharmaceutical's Rule of X is 42% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Yifan Pharmaceutical Competitors
Yifan Pharmaceutical competitors include Intellia Therapeutics, Iovance Biotherapeutics, Bausch Health, Jinyu Bio-Technology Co., Kalbe Farma, TransThera Sciences, Ocular Therapeutix, Mesoblast, Galapagos and Guobang Pharma.
Most Yifan Pharmaceutical public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 22.7x | 24.0x | (3.7x) | (3.7x) | |||
| 5.9x | 5.1x | (4.5x) | (5.0x) | |||
| 2.1x | 2.1x | 6.0x | 5.8x | |||
| 8.2x | 7.6x | 31.4x | 31.9x | |||
| 0.8x | 0.8x | 5.2x | 5.4x | |||
| - | - | (42.3x) | - | |||
| 23.7x | 23.7x | (4.9x) | (3.9x) | |||
| 110.7x | 16.5x | (27.7x) | (68.1x) | |||
This data is available for Pro users. Sign up to see all Yifan Pharmaceutical competitors and their valuation data. Start Free Trial | ||||||
Investments by Yifan Pharmaceutical
Yifan Pharmaceutical has invested in 2 companies to date.
Latest investment by Yifan Pharmaceutical was on June 2nd 2022. Yifan Pharmaceutical invested in Evive Biotech in their $70M Undisclosed stage round (EV/Revenue multiple available to Pro users).
Latest Investments by Yifan Pharmaceutical
| Description | Evive Biotech is a biologics developer advancing therapies for oncology and immunology disorders through its DiKine bispecific fusion protein platform and ITab tumor-targeted immunotherapy platform. Shanghai-headquartered with facilities in Singapore and San Francisco, the company maintains an in-house cGMP manufacturing site compliant with FDA, EMA, and NMPA regulations. Its pipeline features ET-01, a Phase 1 anti-EGFR x TGF-β bispecific antibody for hepatocellular carcinoma, and EB-003, an IL-18 fusion protein for inflammatory bowel disease. Established in 2004, Evive Biotech collaborates with global partners to accelerate clinical progression across multiple indications. | Generon (Shanghai) Corporation Ltd. is a Shanghai-headquartered biotech firm manufacturing recombinant proteins for cancer and autoimmune therapies. The company operates R&D in Zhangjiang Hi-Tech Park and cGMP facilities in Beijing, adhering to FDA, EMA, and CFDA standards. Generon advances biosimilars like etanercept and novel Fc-fusion proteins through Phase I trials. |
| HQ Country | ||
| HQ City | Singapore | Shanghai |
| Deal Date | 2 Jun 2022 | 2 Jun 2022 |
| Round | Undisclosed stage | Undisclosed stage |
| Raised | $70M | $70M |
| Investors | Sino Biopharmaceutical; Yifan Pharmaceutical | Sino Biopharmaceutical; Yifan Pharmaceutical |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Yifan Pharmaceutical investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Yifan Pharmaceutical
| When was Yifan Pharmaceutical founded? | Yifan Pharmaceutical was founded in 1994. |
| Where is Yifan Pharmaceutical headquartered? | Yifan Pharmaceutical is headquartered in China. |
| How many employees does Yifan Pharmaceutical have? | As of today, Yifan Pharmaceutical has over 1K employees. |
| Is Yifan Pharmaceutical publicly listed? | Yes, Yifan Pharmaceutical is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Yifan Pharmaceutical? | Yifan Pharmaceutical trades under 002019 ticker. |
| When did Yifan Pharmaceutical go public? | Yifan Pharmaceutical went public in 2004. |
| Who are competitors of Yifan Pharmaceutical? | Yifan Pharmaceutical main competitors include Intellia Therapeutics, Iovance Biotherapeutics, Bausch Health, Jinyu Bio-Technology Co., Kalbe Farma, TransThera Sciences, Ocular Therapeutix, Mesoblast, Galapagos, Guobang Pharma. |
| What is the current market cap of Yifan Pharmaceutical? | Yifan Pharmaceutical's current market cap is $2B. |
| What is the current revenue of Yifan Pharmaceutical? | Yifan Pharmaceutical's last 12 months revenue is $785M. |
| What is the current revenue growth of Yifan Pharmaceutical? | Yifan Pharmaceutical revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Yifan Pharmaceutical? | Current revenue multiple of Yifan Pharmaceutical is 2.7x. |
| What is the current EBITDA of Yifan Pharmaceutical? | Yifan Pharmaceutical's last 12 months EBITDA is $139M. |
| What is Yifan Pharmaceutical's EBITDA margin? | Yifan Pharmaceutical's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Yifan Pharmaceutical? | Current EBITDA multiple of Yifan Pharmaceutical is 15.1x. |
| How many companies Yifan Pharmaceutical has acquired to date? | Yifan Pharmaceutical hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Yifan Pharmaceutical has invested to date? | As of June 2026, Yifan Pharmaceutical has invested in 2 companies. |
| What was the last Yifan Pharmaceutical investment? | On 2nd June 2022 Yifan Pharmaceutical invested in Evive Biotech, participating in a $70M Undisclosed stage round, alongside Sino Biopharmaceutical. |
| In what companies Yifan Pharmaceutical invested in? | Yifan Pharmaceutical invested in Evive Biotech and Generon (Shanghai) Corporation. |
See public comps similar to Yifan Pharmaceutical
Lists including Yifan Pharmaceutical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

